1
|
Vendrell JA, Ban IO, Solassol I, Audran P, Cabello-Aguilar S, Topart D, Lindet-Bourgeois C, Colombo PE, Legouffe E, D’Hondt V, Fabbro M, Solassol J. Differential Sensitivity of Germline and Somatic BRCA Variants to PARP Inhibitor in High-Grade Serous Ovarian Cancer. Int J Mol Sci 2023; 24:14181. [PMID: 37762485 PMCID: PMC10532320 DOI: 10.3390/ijms241814181] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2023] [Revised: 09/07/2023] [Accepted: 09/14/2023] [Indexed: 09/29/2023] Open
Abstract
PURPOSE The introduction of PARP inhibitors (PARPis) as a treatment option for patients with high-grade serous ovarian cancer (HGSOC) modified the approach of BRCA testing worldwide. In this study, we aim to evaluate the impact of BRCA1 and BRCA2 variants on treatment response and survival outcomes in patients diagnosed in our institution. METHODS A total of 805 HGSOC samples underwent BRCA1 and BRCA2 variant detection by using next-generation sequencing (NGS). Among them, a pathogenic alteration was detected in 104 specimens. Clinicopathological features and germline status were recovered, and alteration types were further characterized. The clinical significance of variant type in terms of response to chemotherapy and to PARPis as well as overall survival were evaluated using univariate analysis. RESULTS In our cohort, 13.2% of the HGSOC samples harbored a pathogenic BRCA1 or BRCA2 variant, among which 58.7% were inherited. No difference was observed between germline and somatic variants in terms of the gene altered. Interestingly, patients with somatic variants only (no germline) demonstrated better outcomes under PARPi treatment compared to those with germline ones. CONCLUSION The determination of the inheritance or acquisition of BRCA1 and BRCA2 alterations could provide valuable information for improving management strategies and predicting the outcome of patients with HGSOC.
Collapse
Affiliation(s)
- Julie A. Vendrell
- Laboratoire de Biologie des Tumeurs Solides, Département de Pathologie et Oncobiologie, CHU Montpellier, Université de Montpellier, 34295 Montpellier, France; (J.A.V.); (I.O.B.); (S.C.-A.)
| | - Iulian O. Ban
- Laboratoire de Biologie des Tumeurs Solides, Département de Pathologie et Oncobiologie, CHU Montpellier, Université de Montpellier, 34295 Montpellier, France; (J.A.V.); (I.O.B.); (S.C.-A.)
| | - Isabelle Solassol
- Unité de Recherche Translationnelle, Institut Régional du Cancer de Montpellier (ICM), 34090 Montpellier, France;
| | - Patricia Audran
- Département d’Anatomo-Pathologie, Institut Régional du Cancer de Montpellier (ICM), Université de Montpellier, 34090 Montpellier, France;
| | - Simon Cabello-Aguilar
- Laboratoire de Biologie des Tumeurs Solides, Département de Pathologie et Oncobiologie, CHU Montpellier, Université de Montpellier, 34295 Montpellier, France; (J.A.V.); (I.O.B.); (S.C.-A.)
- Montpellier BioInformatics for Clinical Diagnosis (MOBIDIC), Molecular Medicine and Genomics Platform (PMMG), CHU Montpellier, 34295 Montpellier, France
| | - Delphine Topart
- Oncologie Médicale, CHU Montpellier, Université de Montpellier, 34295 Montpellier, France; (D.T.); (C.L.-B.)
| | - Clothilde Lindet-Bourgeois
- Oncologie Médicale, CHU Montpellier, Université de Montpellier, 34295 Montpellier, France; (D.T.); (C.L.-B.)
| | - Pierre-Emmanuel Colombo
- Département de Chirurgie Oncologique, Institut Régional du Cancer de Montpellier (ICM), 34090 Montpellier, France;
| | - Eric Legouffe
- Oncologie Médicale, Institut de Cancérologie du Gard, 30900 Nîmes, France;
| | - Véronique D’Hondt
- Département d’Oncologie Médicale, Institut Régional du Cancer de Montpellier (ICM), Université de Montpellier, 34090 Montpellier, France; (V.D.); (M.F.)
| | - Michel Fabbro
- Département d’Oncologie Médicale, Institut Régional du Cancer de Montpellier (ICM), Université de Montpellier, 34090 Montpellier, France; (V.D.); (M.F.)
| | - Jérôme Solassol
- Laboratoire de Biologie des Tumeurs Solides, Département de Pathologie et Oncobiologie, CHU Montpellier, Université de Montpellier, 34295 Montpellier, France; (J.A.V.); (I.O.B.); (S.C.-A.)
- Montpellier Research Cancer Institute (IRCM), Institut National de la Santé et de la Recherche Médicale (INSERM) U1194, University of Montpellier, 34298 Montpellier, France
| |
Collapse
|
2
|
Solassol J, Vendrell J, Senal R, Audran P, Leenhardt F, Quantin X. Challenging BRAF/EGFR co-inhibition in NSCLC using sequential liquid biopsies. Lung Cancer 2019; 133:45-47. [DOI: 10.1016/j.lungcan.2019.05.003] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2019] [Revised: 05/02/2019] [Accepted: 05/04/2019] [Indexed: 11/16/2022]
|
3
|
Solassol J, Quantin X, Larrieux M, Senal R, Audran P, Grand D, Mangé A, Diamandis EP, Vendrell JA. Comparison of five cell-free DNA isolation methods to detect the EGFR T790M mutation in plasma samples of patients with lung cancer. ACTA ACUST UNITED AC 2018; 56:e243-e246. [DOI: 10.1515/cclm-2017-0967] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2017] [Accepted: 02/19/2018] [Indexed: 11/15/2022]
Affiliation(s)
- Jérôme Solassol
- Department of Pathology , CHU Montpellier, University of Montpellier , Montpellier , France
- Department of Biopathology , Institut du Cancer de Montpellier (ICM), University of Montpellier , Montpellier , France
- Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM U1194, University of Montpellier , Montpellier , France
| | - Xavier Quantin
- Department of Thoracic Oncology , CHU Montpellier, University of Montpellier , Montpellier , France
| | - Marion Larrieux
- Department of Pathology , CHU Montpellier, University of Montpellier , Montpellier , France
| | - Romain Senal
- Department of Biopathology , Institut du Cancer de Montpellier (ICM), University of Montpellier , Montpellier , France
| | - Patricia Audran
- Department of Biopathology , Institut du Cancer de Montpellier (ICM), University of Montpellier , Montpellier , France
| | - David Grand
- Department of Pathology , Institut Universitaire du Cancer Toulouse Oncopole, CHU de Toulouse , Toulouse , France
| | - Alain Mangé
- Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM U1194, University of Montpellier , Montpellier , France
| | - Eleftherios P. Diamandis
- Department of Pathology and Laboratory Medicine , Mount Sinai Hospital , Toronto , Canada
- Department of Laboratory Medicine and Pathobiology , University of Toronto , Toronto , Canada
- Department of Clinical Biochemistry , University Health Network , Toronto , Canada
| | - Julie A. Vendrell
- Department of Pathology , CHU Montpellier, University of Montpellier , Montpellier , France
| |
Collapse
|
4
|
Vendrell JA, Taviaux S, Béganton B, Godreuil S, Audran P, Grand D, Clermont E, Serre I, Szablewski V, Coopman P, Mazières J, Costes V, Pujol JL, Brousset P, Rouquette I, Solassol J. Detection of known and novel ALK fusion transcripts in lung cancer patients using next-generation sequencing approaches. Sci Rep 2017; 7:12510. [PMID: 28970558 PMCID: PMC5624911 DOI: 10.1038/s41598-017-12679-8] [Citation(s) in RCA: 73] [Impact Index Per Article: 10.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2017] [Accepted: 09/04/2017] [Indexed: 12/25/2022] Open
Abstract
Rearrangements of the anaplastic lymphoma kinase (ALK) gene in non-small cell lung cancer (NSCLC) represent a novel molecular target in a small subset of tumors. Although ALK rearrangements are usually assessed by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH), molecular approaches have recently emerged as relevant alternatives in routine laboratories. Here, we evaluated the use of two different amplicon-based next-generation sequencing (NGS) methods (AmpliSeq and Archer®FusionPlex®) to detect ALK rearrangements, and compared these with IHC and FISH. A total of 1128 NSCLC specimens were screened using conventional analyses, and a subset of 37 (15 ALK-positive, and 22 ALK-negative) samples were selected for NGS assays. Although AmpliSeq correctly detected 25/37 (67.6%) samples, 1/37 (2.7%) and 11/37 (29.7%) specimens were discordant and uncertain, respectively, requiring further validation. In contrast, Archer®FusionPlex® accurately classified all samples and allowed the correct identification of one rare DCTN1-ALK fusion, one novel CLIP1-ALK fusion, and one novel GCC2-ALK transcript. Of particular interest, two out of three patients harboring these singular rearrangements were treated with and sensitive to crizotinib. These data show that Archer®FusionPlex® may provide an effective and accurate alternative to FISH testing for the detection of known and novel ALK rearrangements in clinical diagnostic settings.
Collapse
Affiliation(s)
- Julie A Vendrell
- CHU Montpellier, Arnaud de Villeneuve Hospital, Department of Pathology, Montpellier, Université de Montpellier, Montpellier, France
| | - Sylvie Taviaux
- CHU Montpellier, Arnaud de Villeneuve Hospital, Department of Pathology, Montpellier, Université de Montpellier, Montpellier, France
| | - Benoît Béganton
- Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM U1194, Université de Montpellier, Institut du Cancer de Montpellier (ICM), Montpellier, France
| | - Sylvain Godreuil
- CHU Montpellier, Arnaud de Villeneuve Hospital, Department of Bacteriology, Université de Montpellier, Montpellier, France
| | - Patricia Audran
- Institut du Cancer de Montpellier (ICM), Department of Biopathology, Montpellier, France
| | - David Grand
- Department of Pathology, Institut Universitaire du Cancer Toulouse Oncopole, CHU de Toulouse, Toulouse, France
| | - Estelle Clermont
- Department of Pathology, Institut Universitaire du Cancer Toulouse Oncopole, CHU de Toulouse, Toulouse, France
| | - Isabelle Serre
- CHU Montpellier, Arnaud de Villeneuve Hospital, Department of Pathology, Montpellier, Université de Montpellier, Montpellier, France
| | - Vanessa Szablewski
- CHU Montpellier, Arnaud de Villeneuve Hospital, Department of Pathology, Montpellier, Université de Montpellier, Montpellier, France
| | - Peter Coopman
- Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM U1194, Université de Montpellier, Institut du Cancer de Montpellier (ICM), Montpellier, France
| | - Julien Mazières
- Thoracic Oncology Department, Larrey Hospital, University Hospital of Toulouse, Toulouse, France
| | - Valérie Costes
- CHU Montpellier, Arnaud de Villeneuve Hospital, Department of Pathology, Montpellier, Université de Montpellier, Montpellier, France
| | - Jean-Louis Pujol
- CHU Montpellier, Arnaud de Villeneuve Hospital, Department of Thoracic Oncology, Université de Montpellier, Montpellier, France
| | - Pierre Brousset
- Department of Pathology, Institut Universitaire du Cancer Toulouse Oncopole, CHU de Toulouse, Toulouse, France.,Laboratoire d'excellence Labex TOUCAN, Toulouse, France
| | - Isabelle Rouquette
- Department of Pathology, Institut Universitaire du Cancer Toulouse Oncopole, CHU de Toulouse, Toulouse, France
| | - Jérôme Solassol
- CHU Montpellier, Arnaud de Villeneuve Hospital, Department of Pathology, Montpellier, Université de Montpellier, Montpellier, France. .,Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM U1194, Université de Montpellier, Institut du Cancer de Montpellier (ICM), Montpellier, France.
| |
Collapse
|
5
|
Lamy PJ, Castan F, Lozano N, Montélion C, Audran P, Bibeau F, Roques S, Montels F, Laberenne AC. Next-Generation Genotyping by Digital PCR to Detect and Quantify the BRAF V600E Mutation in Melanoma Biopsies. J Mol Diagn 2015; 17:366-73. [PMID: 25952101 DOI: 10.1016/j.jmoldx.2015.02.004] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2014] [Revised: 01/21/2015] [Accepted: 02/18/2015] [Indexed: 12/27/2022] Open
Abstract
The detection of the BRAF V600E mutation in melanoma samples is used to select patients who should respond to BRAF inhibitors. Different techniques are routinely used to determine BRAF status in clinical samples. However, low tumor cellularity and tumor heterogeneity can affect the sensitivity of somatic mutation detection. Digital PCR (dPCR) is a next-generation genotyping method that clonally amplifies nucleic acids and allows the detection and quantification of rare mutations. Our aim was to evaluate the clinical routine performance of a new dPCR-based test to detect and quantify BRAF mutation load in 47 paraffin-embedded cutaneous melanoma biopsies. We compared the results obtained by dPCR with high-resolution melting curve analysis and pyrosequencing or with one of the allele-specific PCR methods available on the market. dPCR showed the lowest limit of detection. dPCR and allele-specific amplification detected the highest number of mutated samples. For the BRAF mutation load quantification both dPCR and pyrosequencing gave similar results with strong disparities in allele frequencies in the 47 tumor samples under study (from 0.7% to 79% of BRAF V600E mutations/sample). In conclusion, the four methods showed a high degree of concordance. dPCR was the more-sensitive method to reliably and easily detect mutations. Both pyrosequencing and dPCR could quantify the mutation load in heterogeneous tumor samples.
Collapse
Affiliation(s)
- Pierre-Jean Lamy
- Department of Biology and Oncogenetics, Institut Régional du Cancer de Montpellier, Montpellier, France; Department of Biobank, Institut Régional du Cancer de Montpellier, Montpellier, France.
| | - Florence Castan
- Department of Statistics, Institut Régional du Cancer de Montpellier, Montpellier, France
| | - Nicolas Lozano
- Department of Biology and Oncogenetics, Institut Régional du Cancer de Montpellier, Montpellier, France
| | - Cécile Montélion
- Department of Biology and Oncogenetics, Institut Régional du Cancer de Montpellier, Montpellier, France
| | - Patricia Audran
- Department of Biology and Oncogenetics, Institut Régional du Cancer de Montpellier, Montpellier, France
| | - Frédéric Bibeau
- Department of Biobank, Institut Régional du Cancer de Montpellier, Montpellier, France; Department of Pathology, Institut Régional du Cancer de Montpellier, Montpellier, France
| | - Sylvie Roques
- Department of Biology and Oncogenetics, Institut Régional du Cancer de Montpellier, Montpellier, France
| | - Frédéric Montels
- Department of Biology and Oncogenetics, Institut Régional du Cancer de Montpellier, Montpellier, France
| | - Anne-Claire Laberenne
- Department of Biology and Oncogenetics, Institut Régional du Cancer de Montpellier, Montpellier, France
| |
Collapse
|
6
|
Lopez-Crapez E, Servanton A, Montelion C, Audran P, Benbaziz N, Roques S, Solassol J, Lamy P. R147: Biologie moléculaire des tumeurs : optimisation de la prise en charge par l’élaboration d’arbres décisionnels méthodologiques. Bull Cancer 2010. [DOI: 10.1016/s0007-4551(15)31068-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|